The Chemopreventive Agent Development Research Group promotes and supports research on early chemopreventive agent development, from preclinical studies to phase I clinical trials. The group’s projects aim to identify and develop prevention agents with the potential to block, reverse, or delay the early stages of cancer. The overarching goal is to determine positive and negative predictive values of preclinical models for clinical development.
The group supports and conducts preclinical studies to evaluate potential new drugs and combinations in model systems using emergent knowledge of genetic and biochemical mechanisms, and early phase trials focused on pharmacokinetics, efficacy, and safety. Research includes all classes of agents (e.g., pharmaceuticals, micronutrients) and includes synthesis/extraction, and mechanistic studies (e.g., assays using high-throughput gene analysis technology, cell cultures from high-risk tissue, carcinogenesis-related biochemical activities, and technologies focusing on molecular targets and their modulation) leading to the identification and optimization of promising chemopreventive agents. This group provides scientific and administrative oversight for preclinical chemoprevention agent development up to early phase I research utilizing physiological endpoints in healthy volunteers.
PREVENT Cancer Preclinical Drug Development Program
The group assists extramural investigators to bridge the gap between discovery and clinical testing through management of the PREVENT Cancer Preclinical Drug Development Program. The PREVENT program provides a structure for the introduction of new agents, drugs and vaccines to inhibit, retard or reverse the cancer process. The program was designed to optimize translational opportunities in the clinic, and to provide a mechanism to identify and study efficacy and pharmacodynamics of biomarkers that will help in phase II trials to evaluate drug effects.
Phase 0/I/II Cancer Prevention Clinical Trials Program
This group jointly administers the Phase 0/I/II Cancer Prevention Clinical Trials Program for evaluating new agents, surrogate biomarkers, and technologies.